Abstract 97P
Background
The search for genetic markers of prognosis seems promising for individualization of treatment programs for patients with brain tumors. The aim of our study is to study the dynamics of the concentration of mutant DNA in the BRAF gene in peripheral blood plasma during and after radiation therapy and compare these data with the effect of treatment.
Methods
Digital droplet PCR (ddPCR) was used to determine the concentration of mutant tumor DNA in 209 blood plasma samples (groups included 57 patients with pons tumors and 29 patients with glioma of the other localization). The samples were obtained before the course of RT, during RT (5-8 fraction) and after RT (27-30 fraction). According to the results of radiation therapy, patients were divided into two groups: 1 – the onset of tumor recurrence less than 6 months after the end of the course of RT; 2 – stabilization of the process for 6 months or more after the end of the course of RT.
Results
A significant increase in the relative concentration of mutant (V600E) DNA of the BRAF gene in peripheral blood at the beginning of the RT course and its decrease by the end of the course in the relapse-free group was shown. No changes or an increase in BRAFV600E levels by the end of the RT course was typical for patients with relapse in the early stages.
Conclusions
Methods of liquid biopsy allow to estimate changes in the amount of mutant (tumor) DNA in peripheral blood plasma in children with brain glioma in RT. Increase in the level of mutant DNA correlates with a more stable effect of the treatment.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology (RSCRR) of the Ministry of Healthcare of the Russian Federation (Russian Scientific Center of Roentgenoradiology).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract